Protara Therapeutics (NASDAQ:TARA) Given Buy Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Protara Therapeutics (NASDAQ:TARA) in a research note issued to investors on Tuesday morning,Benzinga reports. They currently have a $23.00 price objective on the stock.

Several other research firms have also recently weighed in on TARA. Piper Sandler began coverage on Protara Therapeutics in a research note on Wednesday, January 7th. They set an “overweight” rating and a $24.00 target price on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Protara Therapeutics in a report on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $20.40.

Protara Therapeutics Stock Down 0.6%

Shares of NASDAQ TARA opened at $6.44 on Tuesday. The stock has a market capitalization of $332.50 million, a P/E ratio of -4.50 and a beta of 1.38. Protara Therapeutics has a 52-week low of $2.77 and a 52-week high of $7.82. The stock’s 50 day moving average price is $5.84 and its two-hundred day moving average price is $4.91.

Protara Therapeutics (NASDAQ:TARA) last issued its earnings results on Monday, November 10th. The company reported ($0.31) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.08. On average, analysts anticipate that Protara Therapeutics will post -3.32 EPS for the current year.

Institutional Trading of Protara Therapeutics

A number of large investors have recently made changes to their positions in TARA. Velan Capital Investment Management LP lifted its position in Protara Therapeutics by 28.3% in the 2nd quarter. Velan Capital Investment Management LP now owns 2,139,000 shares of the company’s stock valued at $6,481,000 after acquiring an additional 471,200 shares in the last quarter. Vanguard Group Inc. increased its position in Protara Therapeutics by 5.7% during the third quarter. Vanguard Group Inc. now owns 1,904,156 shares of the company’s stock worth $8,283,000 after acquiring an additional 102,176 shares during the period. Acorn Capital Advisors LLC lifted its position in shares of Protara Therapeutics by 36.9% during the 2nd quarter. Acorn Capital Advisors LLC now owns 1,752,115 shares of the company’s stock valued at $5,309,000 after acquiring an additional 472,315 shares during the period. UBS Group AG boosted its position in shares of Protara Therapeutics by 44.2% during the 4th quarter. UBS Group AG now owns 1,215,537 shares of the company’s stock worth $6,479,000 after acquiring an additional 372,463 shares in the last quarter. Finally, Geode Capital Management LLC grew its position in Protara Therapeutics by 7.7% in the fourth quarter. Geode Capital Management LLC now owns 817,196 shares of the company’s stock valued at $4,357,000 after acquiring an additional 58,477 shares during the last quarter. Institutional investors own 38.13% of the company’s stock.

Protara Therapeutics Company Profile

Protara Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for virus-driven cancers. The company’s primary areas of research include human papillomavirus (HPV)–associated malignancies, where it seeks to harness and enhance the body’s immune response to target tumor cells. Protara’s therapeutic strategy combines antigen-specific vaccination approaches with modulators of T-cell activation to improve clinical outcomes in patients with HPV-mediated disease.

Protara’s lead immunotherapy candidate is PTX-35, an investigational monoclonal antibody designed to agonize OX40, a co-stimulatory receptor on T cells.